Research ArticleAccepted Article
Open Access
Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Robert R. McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park and Alexis Ogdie
The Journal of Rheumatology April 2021, jrheum.201549; DOI: https://doi.org/10.3899/jrheum.201549
Philip J. Mease
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Robert R. McLean
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Blessing Dube
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Mei Liu
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Sabrina Rebello
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Meghan Glynn
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Esther Yi
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Yujin Park
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Alexis Ogdie
From the Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA; Corrona, LLC, Waltham, MA, USA; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Funding: This study was sponsored by Corrona, LLC. Corrona, LLC, has been supported through contracted subscriptions in the last 2 years by AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Crescendo, Eli Lilly and Company, Genentech, Gilead, GSK, Janssen, Merck, Momenta Pharmaceuticals, Novartis, Ortho Dermatologics, Pfizer Inc, Regeneron, Roche, Sun, and UCB. The design and conduct of the study were a collaborative effort between Corrona, LLC, and Novartis, and financial support for the study was provided by Novartis. Novartis participated in the interpretation of data and review and approval of the manuscript. Conflicts of interest: P.J. Mease has received research grants from AbbVie, Amgen, Bristol Myers Squibb, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB; and consulting and/or speakers bureau fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Galapagos, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, Sun, and UCB. R.R. McLean and B. Dube are employees of Corrona, LLC. E. M. Liu, S. Rebello, and M. Glynn were employees of Corrona, LLC, at the time of this analysis. Yi and Y. Park are employees of Novartis Pharmaceuticals Corporation. A. Ogdie has received consulting fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis, and Pfizer, and has received grant support from the National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Psoriasis Foundation, Rheumatology Research Foundation, Pfizer (University of Pennsylvania), Amgen (FORWARD Databank), and Novartis (FORWARD Databank). Address correspondence to: Philip J. Mease, MD, Seattle Rheumatology Associates, 601 Broadway, Suite 600, Seattle, WA 98122; phone: (206) 386-2000; fax: (206) 386-2083; email: pmease@philipmease.com
Article Figures & Data
Additional Files
201549 Video Abstract
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Robert R. McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, Alexis Ogdie
The Journal of Rheumatology Apr 2021, jrheum.201549; DOI: 10.3899/jrheum.201549
Accepted manuscript
Comparison of Men and Women With Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Robert R. McLean, Blessing Dube, Mei Liu, Sabrina Rebello, Meghan Glynn, Esther Yi, Yujin Park, Alexis Ogdie
The Journal of Rheumatology Apr 2021, jrheum.201549; DOI: 10.3899/jrheum.201549